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Abstract
Melanoma is among the most common cancers for adolescents and young adults. Updated 
information on melanoma among adults < 50 is needed. The objective of this study was to 
examine invasive melanoma in the United States among people aged 15–49 years for the group at 
highest risk, non-Hispanic whites. In 2015, we analyzed population-based cancer registry data 
from the Centers for Disease Control and Prevention’s National Program of Cancer Registries and 
the National Cancer Institute’s Surveillance, Epidemiology, and End Results program to examine 
melanoma incidence and death rates and trends among non-Hispanic whites aged 15–49 years by 
sex and age. We also present incidence trends with regard to thickness and site on the body. 
Among non-Hispanic whites aged 15–49 years, rates were higher among females. Thin 
melanomas increased among both sexes during 1992–2006 and stabilized during 2006–2012. For 
the period 1992–2012, melanomas thicker than 4 mm increased among males and melanomas 
1.01–2.00 mm thick increased among females. Melanomas were most commonly diagnosed on the 
trunk and lower extremity among females and on the trunk and upper extremity among males. 
Increases in melanoma incidence among non-Hispanic whites aged 15–49 years across various 
thicknesses suggest that melanoma trends are not solely related to increased screening but are, in 
part, related to true increases. Declines in melanoma rates of about 3% a year from the mid-2000s 
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to 2012 in the youngest age groups offer hope that melanoma incidence may decline in future 
generations.
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INTRODUCTION
The recent Surgeon General’s Call to Action to Prevent Skin Cancer characterized skin 
cancer as a “major public health problem” because despite known effective prevention 
strategies, incidence continues to increase.1 These increases are resulting in significant 
burdens in the United States, with over 5 million people treated for skin cancer each year at 
a cost of $8.1 billion.2 Melanoma is the skin cancer responsible for the most deaths, and the 
most common skin cancer for which incidence and mortality data are systematically tracked 
in the United States. Over 67,000 cases of invasive melanoma and over 9,000 deaths from 
the disease occurred in 2012.3
Melanoma is among the most common cancers for adolescents and young adults, and the 
second most common cancer among young women aged 20–29 years.3 The highest 
incidence of melanoma occurs among fair-skinned populations, predominantly non-Hispanic 
whites, who have about 25 times the melanoma incidence rate of black populations and 
about 6 times the rate of Hispanic populations.1 Although the incidence of most other 
cancers is decreasing in the United States, melanoma incidence continues to increase.4
The objective of this study was to examine incidence and mortality data for invasive 
melanoma among adolescents and adults younger than age 50. Because of our large data set, 
we were able to characterize the burden of these cancers in the United States. Given the 
higher rates among fair-skinned groups, we focused on non-Hispanic white males and 
females aged 15–49 years. We also provide information on trends, including thickness and 
site on the body, using data including a smaller percentage of the US population.
METHODS
In 2015, we examined population-based cancer registry data from the National Cancer 
Institute’s Surveillance, Epidemiology, and End Results (SEER) program from 1992–2012 
(SEER 13) to demonstrate incidence trends for 13% of the U.S. population, respectively. 
Data from the Centers for Disease Control and Prevention’s (CDC’s) National Program of 
Cancer Registries (NPCR) were combined with SEER data, enabling analysis of incidence 
data on 99.1% of the U.S. population for the years 2008–2012. Cases were coded using the 
International Classification of Diseases version that was current at the time of diagnosis and 
later converted to the 3rd edition (ICD-O-3).5 We included microscopically confirmed 
invasive melanomas of the skin, defined as having an ICD-O-3 site code of C440–C449 and 
ICD-O-3 histology code of 8720–8790. Mortality data covering all deaths in the United 
States are from the CDC’s National Vital Statistics System for the years 2008–2012 (to 
describe current rates and counts) and for the years 1992–2012 (to describe trends).
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We used SEER*Stat software version 8.2.1 to calculate age-adjusted rates per 100,000 
population (based on the 2000 U.S. standard population), rate ratios, 95% confidence 
intervals, and average annual percent change. Rates based on a count of <10 cases were not 
reported. Rate ratios (RRs) were considered to be significant if they differed from 1 at 
p<0.05.
Trends in age-adjusted incidence and death rates were analyzed using the Joinpoint 
Regression Program, which tests whether or not apparent changes in trends are statistically 
significant.6 Joinpoint regression allowing 4 segments was used to fit age-adjusted trends for 
1992–2012. Annual percent change calculated using Joinpoint was considered significant 
when the regression line slope differed from zero (p<0.05).
Cases were limited to non-Hispanic whites only, for the periods 1992–2012 (SEER 13) and 
2008–2012 (NPCR + SEER), using the North American Association of Central Cancer 
Registries Hispanic Identification Algorithm (NHIA) version 2 (NHIAv2.2) and race as 
coded in the medical record. NHIAv2.2 was not available for deaths due to melanoma; these 
analyses were limited to white race only.
RESULTS
Current Melanoma Incidence Rates and Recent Trends (2008–2012)
Table 1 shows current incidence and mortality rates (2008–2012) among non-Hispanic 
whites aged 15–49 years. An average of 13,387 invasive melanomas were diagnosed in this 
population each year, 7,831 among females and 5,556 among males. Incidence rates among 
females aged 15–29 years were more than twice as high as males in the same age group (RR 
2.32; p <0.05). Although rates among females were higher in every age group <50 years, 
rates among both sexes increased with age, and differences between them were attenuated 
with older age (RR 1.59 and 1.17, respectively, for age groups 30–39 and 40–49 years). 
Among females aged 15–49 years, approximately 50% of cases were diagnosed among 
those aged 15–39 years, while among males, the majority of cases (61%) were diagnosed 
among those aged 40–49 years. Trends from 1992–2012, also shown in Figure 1, 
demonstrate that melanoma incidence increased during the time period. The steepest 
increase was among females aged 15–29 years from 1992–2005, with a 4.2% increase each 
year. Melanoma rates for the 15–29 year age group decreased by 3.6% annually from 2004–
2012 among males (p<0.05), and by 3.3% annually from 2005–2012 among females 
(p<0.05) (Table 1).
Melanoma Incidence Rates and Trends by Thickness
Table 2 displays rates and trends in melanoma thickness at diagnosis during 1992–2012. The 
majority of melanomas diagnosed were thin lesions, up to 1 mm thick. Thin lesions 
increased among both males and females during 1992–2006 (3.0% and 4.5% per year, 
respectively) and leveled off between 2006 and 2012. However, lesions 1.01–2.00 mm thick 
increased an average of 2.8% per year among females, and lesions thicker than 4 mm 
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increased by 1.8% each year among males. The rate of melanomas with unknown thickness 
declined for both males and females. Other trends were not statistically significant.
Melanoma Incidence Rates and Trends by Site on Body
Table 3 displays rates and trends in melanoma incidence by body site. Among males, rates 
were highest on the trunk and upper extremities (6.9 and 3.0 per 100,000, respectively); 
among females, rates were highest on the lower extremity, trunk, and upper extremities (6.5, 
6.3, and 4.4, respectively). Increases were most pronounced for melanomas of the trunk and 
lower extremity among females. Among females, melanoma of the trunk increased by 3.9% 
each year during 1992–2005 and melanomas of the lower extremity increased by 3.7% 
annually during 1992–2006.
Current Melanoma Death Rates and Recent Trends
Deaths from melanoma also increased with age, and contrary to incidence, were slightly 
higher among males than females for each age group (Table 1). An average of 1,027 deaths 
occurred among non-Hispanic whites aged 15–49 years each year from 2008–2012, 405 
among females and 622 among males. Death rates decreased during 1992–2012 for both 
sexes and all ages except among males aged 15–29 years, for whom death rates remained 
stable. Melanoma deaths were more common among males than females for all age groups, 
despite higher incidence among females.
DISCUSSION
From 2008–2012, an average of 13,387 melanomas were diagnosed each year among non-
Hispanic whites aged 15–49 years. Rates were higher among females and increased with age 
among both sexes, although age distribution was generally younger among females than 
males. Our analysis examining trends in melanoma incidence from 1992–2012 identified 
increases in incidence across groups, but also identified stabilization or decreases among 
those 15–29 in the most recent years. The decreases in the most recent years may reflect a 
cohort effect, or possibly delayed reporting of melanomas to central cancer registries.7,8
Higher rates among young women, as well as steeper increases, suggest a potential effect of 
intentional tanning, both outdoors and indoors, as has been documented elsewhere.9–12 For 
example, Bradford et al. examined increases in melanoma by age cohort among young 
women and found preferential increases among trunk melanomas diagnosed at younger 
ages.9 This is consistent with studies that have hypothesized that melanoma at different sites 
on the body is associated with different patterns of UV exposure; for example, melanomas 
appearing on the head and neck have been shown to be more strongly associated with 
occupational exposure, while those on the trunk are more strongly associated with 
intermittent exposure.10,11
Higher death rates and higher percentages of thicker tumors diagnosed among males 
indicate that young men may be diagnosed later. Melanoma thickness at diagnosis is 
strongly correlated with melanoma prognosis, as those diagnosed with thicker or later-stage 
melanomas consistently have poorer survival rates.13 Gender differences in stage at 
diagnosis may be related to fewer encounters with health care providers among males than 
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females, or to less awareness of skin lesions generally. 14,15 Later diagnosis among males, 
together with higher death rates, may indicate lack of awareness of skin in general and 
melanoma in particular, and highlight opportunities for increased education and awareness 
efforts, related to both primary prevention and awareness of abnormal lesions.
Although 68% of melanomas among our study population were diagnosed at an early stage, 
with a thickness of 1 mm or less, 21% of cases were diagnosed at later stages. Increases in 
melanoma incidence may be, in part, related to overdiagnosis of potentially indolent 
lesions.16 Screening for skin cancer has become more common in recent years.17 However, 
our study describes increases in both thick and thin lesions, strengthening evidence that 
while some increases in melanoma are likely attributable to increased surveillance and 
diagnosis of in situ or early-stage lesions, increases in 1.01 to 2.00 mm melanomas in 
women and thicker than 4.00 mm melanomas in men are clinically significant and may 
eventually lead to increasing mortality.18,19 Although our study did not show increases in 
mortality among younger men, melanoma mortality is increasing slowly, at about 1% a year, 
among white males in the United States of all ages.4 Since these increases were not apparent 
among younger males, it is likely that they are driven by trends among middle-aged and 
older males. Also, although diagnosis at an early stage improves prognosis, even those 
diagnosed early are at increased risk throughout life. People who are diagnosed with 
melanoma have a nearly 9-fold increased risk of developing a second melanoma, with even 
higher risks for younger people or for those recently diagnosed.20
Declines in melanoma rates of about 3% a year from the mid-2000s to 2012 in the youngest 
age groups offer hope that melanoma incidence may decline in future generations. Evidence 
from Australia has suggested stabilization and declines in melanoma incidence among 
young adolescents and young adults, also primarily limited to early-stage lesions.21 
Australia has invested significant resources in addressing primary prevention and awareness 
of melanoma. Ongoing analysis to determine whether these declines continue in the United 
States, or if they are potentially related to data collection issues or other reasons, will be 
important. If these trends are sustained into the future, this will be the first manuscript to 
document such stabilization or declines.
In order to further examine whether recent stabilization or downward trends were related to 
delays in reporting, we examined delay-adjusted SEER 18 data (not shown). Delay-adjusted 
factors are estimated for broad age groups and do not include Hispanic ethnicity, so we were 
not able to calculate delay adjustment for our data among non-Hispanic whites. However, 
analysis of delay-adjusted data among whites of all ethnicities also demonstrated declines 
among the youngest age groups. These declines were not observed among older populations, 
either in our data or in SEER delay-adjusted data. Using delay-adjusted data allowed us to 
estimate that our 2012 data were undercounted by about 5%. Delay-adjusted rates from 
SEER 13 areas showed less steep increases in melanoma among males and stabilization in 
rates among females in recent years, but information about specific age groups was not 
available.22 Future analyses incorporating delay adjustment methods are needed to clarify 
recent trend data.
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Our study is subject to certain limitations. Melanomas, especially those diagnosed at early 
stages, are often diagnosed and treated in outpatient settings and therefore are prone to 
underreporting and reporting delays.7,23,24 Despite efforts to increase reporting,24 trends in 
the most recent years of our analysis may be affected by these reporting delays. Unknown 
tumor size became less common during our years of study. Increases by tumor size could 
have partially reflected tumors being assigned a size code, rather than unknown. In addition 
to uncertainty related to reporting issues, we were unable to examine skin type, sun 
sensitivity, or behavioral risk factors in this analysis, because those data are not available in 
cancer registries. Finally,although we examined melanomas diagnosed among young non-
Hispanic white adults aged 15–49 years, we used fairly broad age groups to enhance the 
stability of rates. There are substantial differences in incidence within age groups, 
particularly those aged 15–29 years.
CONCLUSION
In conclusion, this analysis provides a detailed look at trends in melanomas diagnosed 
among young non-Hispanic whites in the United States. Increases in melanoma incidence 
across various thicknesses suggest that melanoma trends are not solely related to increased 
screening but are, in part, true increases. Decreases in melanoma incidence from the 
mid-2000’s to 2012 for both males and females aged 15–29 could indicate the first signs of 
stabilization in increasing melanoma rates. Later stage at diagnosis and higher death rates 
among males are concerning and indicate the need for increased awareness.
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• Over 13,000 invasive melanomas are diagnosed annually among young 
non-Hispanic whites.
• Most diagnoses are thin lesions, but some thicker lesions are 
increasing.
• Young women had higher rates and steeper increases of melanoma 
incidence.
• Recent trends among those age 15–29 may suggest stabilization in 
rates.
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Melanoma incidence rates by age and year of diagnosis among non-Hispanic whites aged 
15–49, SEER, 1992–2012
Rates are per 100,000 persons and are age-adjusted to the 2000 U.S. standard population (19 
age groups – Census P25–1130).
Source for trend data: Surveillance, Epidemiology, and End Results (SEER) Program 
(www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 13 Regs Research Data, 
Nov 2014 Sub (1992–2012) <Katrina/Rita Population Adjustment> - Linked To County 
Attributes - Total U.S., 1969–2012 Counties, National Cancer Institute, DCCPS, 
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Surveillance Research Program, Surveillance Systems Branch, released April 2015, based 
on the November 2014 submission.
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